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Abstract Background and Objectives: Facial angiofibromas are disfiguring facial
lesions, present in up to 80% of patients with tuberous sclerosis complex.
Recent elucidation of the complex cell signaling pathways that are disrupted
in tuberous sclerosis indicates that rapamycin may be successful in alleviating
the appearance of these lesions. The objectives of the current study were to
evaluate the safety of topically applied rapamycin in patients with tuberous
sclerosis complex and to determine its potential effectiveness in treatment of
facial angiofibromas.
Patients and Methods: The study was a prospective, randomized, double-
blind, placebo-controlled study performed at the University of Texas Health
Science Center at Houston. Study subjects were recruited from the patient
populations at the University of Texas Tuberous Sclerosis Center of Ex-
cellence. All subjects were over the age of 13 years and had a diagnosis of
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form of rapamycin or if they were pregnant. Study subjects applied the study
product to their facial angiofibromas nightly for a duration of 6 months. The
investigational product contained one of three doses of rapamycin com-
pounded with Skincerity : (i) no rapamycin; (ii) 1mg of rapamycin per 30 cc
(0.003%); or (iii) 5mg of rapamycin per 30 cc (0.015%). Plasma rapamycin
concentrations were measured monthly to test for systemic absorption.
Complete blood counts were performed monthly to test for anemia, neutro-
penia, or thrombocytopenia. Upon completion of the trial, subjects were
asked if the formulation had improved the appearance of their facial angio-
fibromas.
Results: Twenty-three subjects completed the study. There was no detect-
able systemic absorption of rapamycin (all blood concentrations were
<1.0ng/mL). There were no significant changes in white blood cell, red blood
cell, or platelet counts. Seventy-three percent of subjects in the treatment
arms versus 38% of subjects in the placebo arm reported a subjective im-
provement in the appearance of their facial angiofibromas.
Conclusion: Theapplicationoflow-dose topicalrapamycin(0.003–0.015%)to
thefacecan safelydecreasetheappearanceoffacial angiofibromas inpatients
with tuberous sclerosis complex.
Trial Registration: ClinicalTrials.gov Identifier: NCT01031901
Tuberous sclerosis complex (TSC) is an auto-
somal-dominant genetic disorder characterized
by the formation of benign tumors in multiple
organ systems. Facial angiofibromas appear as
red or pink papules over the central face, espe-
cially on the nasolabial folds, cheeks, and chin,[1]
in people with TSC. Lesions arise in early child-
hood and are present in up to 80% of TSC
patients.[1,2] In some patients, the lesions become
confluent and can result in severe disfigurement.
Although multiple treatments have been devel-
oped to alleviate the appearance of facial angio-
fibromas – curettage, cryosurgery, chemical peels,
dermabrasion, shave excisions, and laser therapy[3-8]
– these are uncomfortable and need to be re-
peated at periodic intervals to treat recurrence.[9]
In patients with TSC, the mammalian target of
rapamycin (mTOR) is aberrantly activated in fi-
broblast-like cells located within the dermal layer
of the skin. These cells produce an epidermal
growth factor, epiregulin, which stimulates epi-
dermal cell proliferation.[10] Epidermal cells are
producedatafasterratethantheabilitytoslough
the dead cells from the skin surface.[11] This
overproduction of skin cells, in conjunction with
angiogenesis, results in the initial appearance and
continued progression of facial angiofibromas
over time.
Recent elucidation of the complex signaling
relationship between the tuberous sclerosis 1
(TSC1) and tuberous sclerosis 2 (TSC2) gene
products and mTOR has led to an explosion of
research related to the use of mTOR inhibitors,
such as rapamycin, in TSC. These mTOR inhibi-
tors are showing promise in treating multiple tumor
types, including renal angiomyolipomas (AMLs),
sub-ependymal giant cell astrocytomas (SEGAs),
and lymphangioleiomyomatosis (LAM).[12-15]
Rapamycin is a naturally occurring antifungal
macrolide, first isolated from Streptomyces hy-
groscopicus in 1965. Rapamycin binds with high
specificity to mTOR, and binding results in in-
hibition of mTOR activity and ultimately in
downregulation of cell growth.[16] Rapamycin
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lowing for its absorption through the super-
ficial layers of the epidermis to the deep dermal
layer implicated in the development of facial
angiofibromas.
The primary goal of this study was to evaluate
the safety of topical rapamycin (0.003% and
0.015%) in patients with TSC. The secondary
goal of this study was to evaluate the efficacy
of the topical product for treatment of facial
angiofibromas.
Methods
Patient Selection
After approval was obtained from the institu-
tional review board at the University of Texas
Health Science Center (UTHSC) at Houston,
study subjects were recruited from the patient
population at the Tuberous Sclerosis Center of
Excellence at the University of Texas Medical
School at Houston from January 2010 through
August 2010. All subjects were over the age of
13 years and had a clinical diagnosis of tuberous
sclerosis complex.[17] Subjects were excluded if they
were currently pregnant, were using oral rapa-
mycin, or had any form of immune dysfunction.
After completing an informed consent document,
willing participants who satisfied the inclusion
and exclusion criteria (table I) were enrolled in
the study. The study participants provided demo-
graphic data, including age, sex, and race, dur-
ing the initial interview. Race/ethnicity was defined
by the participants.
Protocol Summary
Upon enrollment, subjects were randomized
and provided with a bottle of the investigational
product. The investigational product contained
one of three doses of rapamycin compounded
with Skincerity : (i) no rapamycin; (ii) 1mg of
rapamycin per 30 cc (0.003%); or (iii) 5mg of ra-
pamycin per 30 cc (0.015%). Subjects applied a
thin coating of the investigational product to the
skin directly over the treatment area every even-
ing for 6 months. The product was allowed to air
dry for 60 minutes following application and was
removed by gentle washing in the morning. Sub-
jects were monitored monthly in the study clinic,
where blood was drawn to measure serum rapa-
mycin concentrations, the study product was ex-
amined, and photographs were taken. The study
product was replenished as needed.
Rapamycin concentrations were analyzed at
the University of Texas Medical School at
Houston rapamycin laboratory, using an Archi-
tect i1000 analyzer (Abbott Laboratories, Abbott
Park, IL, USA).
The investigational product was manufactured
at nocost byBiomedical Development Corporation
(San Antonio, TX, USA) by combining sirolimus
with Skincerity . The company randomized the
investigational product. The researchers and study
subjects were not provided with the randomiza-
tion information until all data had been collected.
Biomedical Development Corporation had no
role in the design of the trial; in the collection,
analysis, or interpretation of the data; or in the
writing of this manuscript. The authors vouch for
the accuracy and completeness of the reported
data.
Data Collection and Statistical Methods
Upon completion of the trial, subjects were
asked if they ‘‘got better on the treatment’’, if
Table I. Inclusion and exclusion criteria for study participation
Inclusion criteria
  Male and female patients aged 13 years and older
  Patients with a clinical diagnosis of tuberous sclerosis
complex[17] and visible facial angiofibromas
  Patients willing and able to comply with the requirements of the
study
Exclusion criteria
  Sexually active women of childbearing potential not using
adequate contraception
  Pregnant women or nursing mothers
  Patients with immune dysfunction or receiving any form of
immunosuppression
  Patients currently receiving therapy with rapamycin
  Patients currently participating, or having participated within the
last 30 days, in any clinical trial involving an investigational drug
product
  Patients with known hypersensitivity to any component of the
study product
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treatment made no difference’’. Statistical anal-
ysis was performed using a two-sided Fischer’s
exacttest.Ateachstudyvisit,bloodwasdrawnto
measure serum rapamycin concentrations and
complete blood counts to assess for systemic ab-
sorption of the study product.
Results
Patient Demographics
A total of 28 patients met the criteria for enroll-
ment in the study: 15 men (54%) and 13 women
(46%). The mean patient age at the time of study
enrollment was 23 years; 72% of the patients were
non-Hispanic Whites, 7% were Hispanic, 10%
were African American, 7% were Asian, and 4%
were Native American (table II). No subject who
was invited to participate refused. Two subjects
withdrew from the study, secondary to discomfort
with product application (a burning sensation
with application). Two subjects were withdrawn
by the investigators, secondary to poor compliance
with study protocols. One subject was withdrawn
following prolonged hospitalization unrelated to
the study product. Twenty-three subjects com-
pleted the entire study protocol.
Rapamycin Concentrations
Blood was drawn at each study visit to measure
serumrapamycinconcentrations.Thelimitofquan-
titation of this immunoassay was 1.0ng/mL, and no
subjectreachedthatconcentrationduringtreatment.
Complete Blood Counts
Complete blood counts were performed by
Quest Laboratories. No subject demonstrated a
significant change in the white blood cell count,
hemoglobinlevel,orplateletcountduringtreatment.
Lesion Appearance
Of the 23 subjects who completed the study,
73% in the treatment arms reported that ‘‘they
got better on the treatment’’, versus 38% of sub-
jects in the placebo arm (figure 1) [p=0.18].
Twenty-seven percent of subjects in the treatment
arms reported that ‘‘the treatment made no differ-
ence’’, versus 62% of subjects in the placebo arm.
No subject reported that they ‘‘got worse on the
treatment’’. There was no statistically significant
difference in the response between subjects on
high-dose and low-dose treatment.
Serious Adverse Events
Among the study subjects, a serious single ad-
verse event occurred in a patient in the low-dose
arm of the study. This subject aspirated during a
seizure and developed pneumonia, which pro-
gressed to septic shock. His rapamycin concen-
trations were undetectable at the time of hospital
admission, and he was immediately withdrawn
from the study. His illness required prolonged hos-
pitalization, but he has since made a full recovery.
Discussion and Conclusion
TSC is a genetic disorder affecting 1 in 6000
individuals worldwide. It is characterized by ab-
normal skin pigmentation and tumor formation
in multiple organ systems. Facial angiofibromas
arebenignskintumorsfoundonthefacesofpatients
with TSC, and the angiofibromatous lesions ap-
pear as red or pink papules distributed over the
centralface,most notably onthenasolabialfolds,
Table II. Patient demographic data
Characteristic Placebo
(n)
Rapamycin (n) Total
(n [%]) High-dose Low-dose
Age (years)
13–18 3 2 3 8 [29]
19–24 3 3 5 11 [39]
25–30 1 1 0 2 [7]
>30 3 3 1 7 [25]
Sex
Male 4 6 5 15 [54]
Female 6 3 4 13 [46]
Race
White, non-Hispanic 6 7 7 20 [72]
White, Hispanic 2 0 0 2 [7]
African American 0 2 1 3 [10]
Asian 1 0 1 2 [7]
Native American 1 0 0 1 [4]
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h o o dan dar ep re s en ti nu pt o80 %ofTSC patients,
creating considerable cosmetic morbidity.
Since the initial descriptions of facial angiofi-
bromas in the 19th century, multiple treatments
have been developed, attempting to alleviate the
appearance of these lesions, including curettage,
cryosurgery, chemical peels, dermabrasion, shave
excisions, and laser therapy. Although the majority
of these treatments are initially effective, they are
uncomfortable, and over time the lesions recur.
Recent case reports and small case series have
demonstrated that a topical rapamycin formula-
tion might be efficacious,[18-27] but prior reports
have consisted of small series without placebo
arms. The primary goal of this study was to de-
termine whether our topical formulation of ra-
pamycin was safe for topical use in the treatment
of facial angiofibromas in patients with TSC.
Thestudywasdesigned toseeifapplication ofthe
investigational product resulted in detectable sys-
temic absorption of the rapamycin. The second-
ary goal of this study was to evaluate whether the
topical product decreased the appearance of the
facial angiofibromas after 6 months of usage, as
self-reported by the subjects. Twenty-three study
subjects applied either a placebo or the inves-
tigational product nightly to their lesions for
6 months. The study results showed that there were
no serious adverse events related to the study
product and there was no detectable systemic
absorption of the rapamycin during the study
period. This study was not powered to reach
statistical significance, and although it did not,
almost twice as many subjects in the combined
treatment arms reported subjective improve-
ments (73%) when compared with the placebo
arm (38%). The observed effect could result
from a treatment effect of the vehicle itself, but
these results suggest that topical application of
our study product is effective in improving the
appearance of facial angiofibromas in people
with TSC. Future studies will include more de-
tailed monitoring of efficacy, including stan-
dardized photography and monthly quality-of-
life questionnaires.
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